Navigation Links
NephRx Corp. Receives Orphan Drug Designation for NX001 for Prevention of Delayed Kidney Graft Function
Date:8/18/2010

sents a well-defined condition where we hope to show that NX001 can improve near-term kidney function in Phase II trials planned for mid-2011."

Orphan drug is a designation by the U.S. FDA under the Orphan Drug Act confirming that a new drug in development is intended to treat a rare disease, defined as those that affect fewer than 200,000 persons in the United States.  Sponsors of drugs granted orphan designation qualify for tax credits and marketing exclusivity incentives.

About NephRx NephRx Corporation is a biotechnology company dedicated to the discovery and development of therapeutic products for the treatment of acute kidney failure and other renal disorders and diseases of the gastrointestinal tract, including mucositis, Crohn's disease and ulcerative colitis.  Lead product NX001 is a kidney growth factor peptide for acute renal failure that is currently in preclinical development for treatment of delayed graft function in transplant patients.  NX002, a derivative of a naturally occurring growth factor, is in preclinical development as a treatment for oral mucositis, a common, painful and dose-limiting side effect of chemotherapy and radiation therapy in patients with head and neck and other cancers.  For more information, visit www.nephrx.com.Contacts:Corporate:  Media:NephRx Corp.

GendeLLindheim BioCom PartnersPhilip A. Long

Barbara Lindheim (269) 838-4785

(212) 918-4650
'/>"/>

SOURCE NephRx Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. BioSpecifics Technologies Corp. Reports Second Quarter 2008 Financial Results
2. InstaCare Corp. Continues Turnaround & Reports 291% Revenues Increase in 2Q 2008
3. ThermoGenesis Corp. to Announce Fourth Quarter and Year End Results for Fiscal 2008 on September 9, 2008
4. BioSpecifics Technologies Corp. Buys Down Royalties for Peyronies Disease
5. Aegis Analytical Corp. Showcases Discoverant at Inaugural Venture Capital in the Rockies Fall
6. BioElectronics Corp. Announces $400,000 in New Orders From the Middle East
7. BioSpecifics Technologies Corp. Announces Appointment of Dr. Matthew Geller to Board of Directors
8. Cantel Medical Corp. To Hold Conference call to Discuss Fourth Quarter and Fiscal 2008 Results
9. Helix BioPharma Corp. Announces Fiscal 2008 Results
10. Sharps Compliance Corp. Announces Appointment of John R. Grow as President and Chief Operating Officer
11. ThermoGenesis Corp. to Announce First Quarter Fiscal 2009 Results on November 6, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... 22, 2015 Selexis SA, a serial ... Cell Banks (RCBs) used for drug discovery to commercial ... will include Next-Generation Sequencing (NGS) data packages. ... biologic manufacturing by ensuring the integrity of the gene, ...
(Date:1/22/2015)... Medical Systems (NYSE: VAR ), world leader in ... to sustainability with inclusion on a prestigious list of the ... equipment company among the Corporate Knights Global 100 Most Sustainable ... Davos, Switzerland . "We ...
(Date:12/24/2014)...  United Therapeutics Corporation (NASDAQ: UTHR ) announced ... has submitted a pre-market approval application to the U.S. ... Medtronic,s SynchroMed ® II implantable drug infusion system ... Therapeutics, Remodulin ® (treprostinil) Injection delivered intravenously to ...
(Date:12/24/2014)... 2014 “Preparative & Process Chromatography ... Consumables (Columns, Solvents, Buffers, Valves, Guages, Seals), Accessories, ... - Forecasts to 2019” provides a detailed overview ... market trends, and strategies impacting the preparative and ...
Breaking Biology Technology:Selexis Generated Research Cell Banks Now Fully Sequenced Using Next-Generation Sequencing 2Varian Honored Among World's 100 Most Sustainable Corporations 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 3United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 4Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 2Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 3Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 4
... Even with layoff announcements from more than a dozen employers in health ... in the past month it seemed like no one was searching for ... ... Strong growth continues in the health care field, with an average of ...
... PHILADELPHIA, Oct. 30 AVAX Technologies, Inc.,(OTC Bulletin ... October,24, 2008, it closed a bridge loan financing ... as amended by the Amendment to Convertible,Note and ... Agreement, the Company sold convertible promissory notes,(the "Notes") ...
... N.J., Oct. 30 Medarex, Inc.,(Nasdaq: MEDX ) announced ... Medarex,s net loss for the quarter ended September 30, ... a net loss of $51.6 million,or ($0.41) per share, for ... a non-cash charge of $5.4 million, or ($0.04) per share, ...
Cached Biology Technology:The MedZilla Report: September 2008 Employment Outlook for Biotech/Pharma/Health 2The MedZilla Report: September 2008 Employment Outlook for Biotech/Pharma/Health 3AVAX Technologies, Inc. Announces Closing of Bridge Loan Financing 2Medarex Announces 2008 Third Quarter Financial Results 2Medarex Announces 2008 Third Quarter Financial Results 3Medarex Announces 2008 Third Quarter Financial Results 4Medarex Announces 2008 Third Quarter Financial Results 5Medarex Announces 2008 Third Quarter Financial Results 6Medarex Announces 2008 Third Quarter Financial Results 7Medarex Announces 2008 Third Quarter Financial Results 8Medarex Announces 2008 Third Quarter Financial Results 9
(Date:12/17/2014)... Valencell, a leader in performance biometric data sensor technology, ... such as Intel, Jabra, Atlas, and Scosche to develop ... products will be showcased at CES 2015, taking place ... "Our partners choose PerformTek biometrics, because ...
(Date:12/17/2014)... DENVER , Dec. 16, 2014  Automation is fundamentally ... evident than at international borders. Over the past decade, ... veteran travelers to self process through border control via ... increasing number of airports, seaports, and land borders across ...
(Date:12/11/2014)... Research and Markets , ... announced the addition of the "Biometrics Market in ... One major trend emerging in this market ... it is important to upgrade biometric solutions to the ...
Breaking Biology News(10 mins):Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2Automated Border Control (ABC) Transforms the Global Travel Experience With More Than 2500 ABC eGates and APC Kiosks Deployed In Airports, Seaports, and Land Borders Worldwide 2Biometrics Market in the APAC Region 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2
... over, oil, gasoline, and coal. Researchers are describing key ... energy-hungry world in the 21st Century in the eighth ... Challenges/Chemistry Solutions series. Those fuels include "green gasoline," "designer ... can help power an energy-hungry world into the future. ...
... been a focal point of recent climate change research because ... the larger Antarctic ice sheet. Yet while the southern Greenland ... how much this is contributing to rising sea levels, and ... was defined at a recent workshop organised by the European ...
... N.J. and Jamaica Plain, Mass., November 3, 2008 ... Biologic Laboratories (MBL) of the University of Massachusetts ... 2 trial of an anti- C. difficile ... difficile Associated Diarrhea (CDAD) successfully met its ...
Cached Biology News:Fuels of the future may come from 'ice that burns,' water and sunshine 2What is really happening to the Greenland icecap? 2Positive results in Phase 2 trial of treatment of C-difficile-associated diarrhea 2Positive results in Phase 2 trial of treatment of C-difficile-associated diarrhea 3
No description available in Ensembl Antigen: Recombinant Protein Epitope Signature Tag (PrEST)....
No description available in Ensembl. Antigen: Recombinant Protein Epitope Signature Tag (PrEST)....
12(S)-HETE-d8 is used as an internal standard for the quantification of 12(S)-HETE by stable isotope dilution mass spectrometry....
...
Biology Products: